Heart failure & cardiomyopathiesRandomised controlled trial
Efficacy and Safety of Hypertonic Saline Therapy in Ambulatory Patients with Heart Failure: The SALT-HF Trial
- Randomised controlled trial
- multicentre
- double-blind
Authors' conclusion
A single infusion of ivFurosemide-HSS did not improve 3-h diuresis or congestion parameters in patients with ambulatory WHF. This therapy showed an appropriate safety profile.
Study context
- Population
- Ambulatory patients with worsening heart failure (HF), 13 sites, December 2020–March 2023
- Participants
- 167 patients
- Comparison
- ivFurosemide-HSS vs ivFurosemide
- Primary endpoint
- Volume of diuresis
- Follow-up
- 3 h
Primary result
As reported in the abstract
3-h diuresis
P = 0.963
Secondary outcomes
WHF · 30 days
HR 0.76 · P = 0.330
All-cause death or HF hospitalization · 30 days
HR 0.69 · P = 0.521
| Outcome | Estimate | P value |
|---|---|---|
| 3-h natriuresis | ∆ +2.642 mEq/L | P = 0.559 |
| 3-h weight | ∆ +0.012 kg | P = 0.920 |
| Weight at 7 days · significant weight decrease with ivFurosemide-HSS | Δ −0.586 kg | P = 0.048 |
Clinical congestion score, biomarkers, inferior vena cava diameter, lung ultrasound B-lines · 7 days
- No between-treatment differences
Safety
Worsening kidney function or metabolic derangements
- Not significantly different between arms
Original publication
Efficacy and Safety of Hypertonic Saline Therapy in Ambulatory Patients with Heart Failure: The SALT-HF Trial. Eur J Heart Fail. Published 26 July 2024. doi:10.1002/ejhf.3390
Summarised from the published abstract; every number is checked against it